EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Postoperative conventional versus hypofractionated intensity-modulated radiation therapy with concurrent chemotherapy in cervical cancer: a prospective multicenter randomized phase III trial (POHIM_P3 trial)

Won Kyung Cho iD, Won Park iD, Jong Hoon Lee iD, Hyun-Cheol Kang iD, Meesun Yoon iD, Keun-Yong Eom iD, Yeon-Sil Kim iD, Sangjoon Park iD, Young Seok Kim iD, Yeon Joo Kim iD, Euncheol Choi iD, Dong-Yun Kim iD

Journal of Gynecologic Oncology · 2026

DOI: 10.3802/jgo.2026.37.e4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Won Kyung Cho und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Radiotherapy, Intensity-Modulated, Chemoradiotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: MOHW, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: For patients with high-risk factors such as pelvic lymph node metastasis, positive surgical margins, or parametrial involvement, concurrent chemoradiotherapy (CCRT) with whole-pelvic radiotherapy significantly improves survival outcomes. Hypofractionated radiation therapy, which delivers higher radiation doses over fewer sessions, enhances tumor control but raises concerns about increased normal tissue toxicity. A recent Korean phase II study (POHIM-CCRT) evaluated the safety of hypofractionated intensity-modulated radiation therapy (IMRT), delivering 40 Gy in 16 fractions with weekly cisplatin following radical surgery. The results showed minimal acute toxicity. Based on these findings, the present study was designed to assess the oncologic efficacy of hypofractionated CCRT compared to conventional treatment strategies in high-risk cervical cancer patients after radical surgery. METHODS: The POHIM-P3 trial is a phase 3, randomized, multicenter study designed for women with cervical cancer requiring adjuvant CCRT after radical hysterectomy. Participants in the experimental arm receive hypofractionated IMRT to whole pelvis, delivering a total dose of 40 Gy in 16 fractions, and the control arm receive conventional radiotherapy with a total dose of 45-50.4 Gy in 25-28 fractions in combination with weekly cisplatin. The primary endpoint of the study is the 3-year disease-free survival and the secondary endpoints included acute and late side-effects, local control rates, and overall survival rates. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06509724.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsRadiotherapy, Intensity-ModulatedChemoradiotherapyHumansFemaleRadiation Dose HypofractionationProspective StudiesMiddle AgedCisplatinAdultHysterectomyAgedClinical Trials, Phase III as TopicRandomized Controlled Trials as TopicMulticenter Studies as Topic

Stichwörter der Autor:innen

Cervical CancerIntensity-Modulated Radiotherapy, Radiation Dose HypofractionationRadiotherapy

Substanzen

Cisplatin

Autor:innen und Institutionen

  • Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. wonro.park@samsung.com.
  • Department of Radiation Oncology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
  • Department of Radiation Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea.
  • Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea.

ORCID-Profile: Won Kyung Cho, Won Park, Jong Hoon Lee, Hyun-Cheol Kang, Meesun Yoon, Keun-Yong Eom, Yeon-Sil Kim, Sangjoon Park, Young Seok Kim, Yeon Joo Kim, Euncheol Choi, Dong-Yun Kim

Förderung

  • MOHW
  • Ministry of Health and Welfare

Zitieren

APA

Cho, W. K., Park, W., Lee, J. H., Kang, H. C., Yoon, M., Eom, K. Y., Kim, Y. S., Park, S., Kim, Y. S., Kim, Y. J., Choi, E., & Kim, D. Y. (2026). Postoperative conventional versus hypofractionated intensity-modulated radiation therapy with concurrent chemotherapy in cervical cancer: a prospective multicenter randomized phase III trial (POHIM_P3 trial). Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2026.37.e4

Vancouver

Cho WK, Park W, Lee JH, Kang HC, Yoon M, Eom KY, et al. Postoperative conventional versus hypofractionated intensity-modulated radiation therapy with concurrent chemotherapy in cervical cancer: a prospective multicenter randomized phase III trial (POHIM_P3 trial). Journal of Gynecologic Oncology. 2026. doi:10.3802/jgo.2026.37.e4

BibTeX
@article{Cho2026,
  author = {Cho, Won Kyung and Park, Won and Lee, Jong Hoon and Kang, Hyun-Cheol and Yoon, Meesun and Eom, Keun-Yong and Kim, Yeon-Sil and Park, Sangjoon and Kim, Young Seok and Kim, Yeon Joo and Choi, Euncheol and Kim, Dong-Yun},
  title = {Postoperative conventional versus hypofractionated intensity-modulated radiation therapy with concurrent chemotherapy in cervical cancer: a prospective multicenter randomized phase III trial (POHIM_P3 trial)},
  journal = {Journal of Gynecologic Oncology},
  year = {2026},
  doi = {10.3802/jgo.2026.37.e4}
}
Kostenlos starten →